Biomerica BMRA

NASDAQ BMRA
$1.55 -0.06 (-3.73%)
At close: Nov 9, 2026 · 4:00 PM EST

Biomerica (BMRA) stock price is $1.55, down 3.73% on the day, as of Nov 9, 2026. It has a market cap of $5.11Mn, and is classified in the Diagnostic Equipment industry (Healthcare sector).

Key Stats
Market Cap5.11 Mn
P/E-1.02
FCF (Yr)-3.42 Mn
ROA (Yr)-59.43
EV to EBIT0.52
Net Income (Yr)-3.78 Mn
Enterprise Value-2.81 Mn
Add ratio to table…

About

Biomerica is a global biomedical technology company that develops patents manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits analyze blood urine nasal or fecal specimens to detect diseases food intolerances bacteria hormones antibodies antigens and other substances present in minute concentrations. The products aim to improve health and lower healthcare costs. They are sold worldwide mainly to clinical laboratories and point of…

Read more ↓
Sector: Healthcare Sector rationale Biomerica develops, manufactures, and markets diagnostic test kits for detecting diseases and food intolerances, which falls directly under the Medical Devices or Diagnostic Equipment industries within Healthcare. Its primary customers are clinical laboratories, hospitals, and physicians, and its revenue is derived from the sale of these medical diagnostic products. Industry: Diagnostic Equipment Diagnostic Equipment Primary Biomerica manufactures and sells diagnostic test kits, such as the hp detect and inFoods IBS tests, which analyze specimens to detect diseases and bacteria. These products are sold as diagnostic machines/tests to clinical laboratories and point-of-care settings, fitting the H-08 profile of selling the test rather than performing the service. Classified using BQ-MICS CIK: 0000073290

Geographical Breakdown of Revenue (2026)

History
Peer percentiles

How Biomerica ranks

Ranked against the 247 companies in Medical Devices and Diagnostics58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −1.06xMedian 26.9x 25th
  • P/FCFNegative free cash flow −1.34xMedian 26.4x 22nd
  • P/Operating cash flowNegative operating cash flow −1.34xMedian 21.3x 20th
  • P/S 1.22xMedian 2.88x 74th
  • P/B 1.45xMedian 2.30x 63rd
  • P/Tangible book 1.54xMedian 2.97x 68th
  • EV/EBITDANegative EBITDA −0.57xMedian 17.5x 9th
  • EV/EBITNegative EBIT −0.57xMedian 26.6x 11th
  • EV/Revenue 0.71xMedian 3.14x 90th
  • EV/FCFNegative free cash flow −0.78xMedian 29.7x 11th
  • EV/Operating cash flowNegative operating cash flow −0.78xMedian 21.1x 11th
  • PEG (3Y EPS CAGR)Negative earnings −0.05Median 0.89 Not meaningful —
Peer group

Peer Comparison

Companies in the Diagnostic Equipment
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 267.71 Bn37.865.6541.37 Bn
2 ABT Abbott Laboratories 191.69 Bn40.783.9731.16 Bn
3 DHR Danaher Corp /De/ 166.18 Bn38.376.4926.48 Bn
4 ISRG Intuitive Surgical Inc 161.07 Bn54.4713.91-
5 MDT Medtronic plc 131.65 Bn25.173.5128.15 Bn
6 SYK Stryker Corp 125.25 Bn34.574.7614.93 Bn
7 BSX Boston Scientific Corp 63.85 Bn18.233.0311.95 Bn
8 BMRA Biomerica Inc 0.01 Bn-1.021.180.00 Bn